Genemarkers Sponsors Rare Disease Challenge
News May 02, 2013
Genemarkers will be providing Genomics Expression Analysis for Silveira’s research on Chronic Beryllium Disease (CBD). Silveira was selected out of 77 applicants covering 67 types of rare disease.
"We are thrilled to be part of the Rare Disease Challenge and to have the opportunity to assist Lori Silveira,” says Dr. Anna Langerveld, president and CEO of Genemarkers. “We are proud that our team of experienced genomics scientists can assist in advancing this research.”
Genemarkers joins 19 other companies as service donors for the competition, hosted by Assay Depot and Rare Genomics Institute. Rare Genomic Institute’s expert panel and a Genemarkers technical expert selected winners for the service donation. The total value of all services reached $500,000, which will go towards helping accelerate rare disease research. To view all service winners and company donations, please visit http://challenge.assaydepot.com/rare-disease-awards.
The competition also features a $10,000 prize with the winner being chosen by Facebook voting. The community can participate by voting for their favorite research proposals on Facebook at http://www.facebook.com/raregenomics.
Genemarkers will work with Lori Silveira over the next few months and push Chronic Beryllium Disease (CBD) research to a new level.
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.